Intellectia LogoIntellectia
Stock
Crypto
Features
Resources
Company
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo
StockCrypto

Features

Pre Market Movers
Financial AI Agent
Swing Trading
Stock Technical Analysis
Stock Monitor
Copy Top Investors Portfolio
Crypto Technical Analysis
Chart Pattern Signal

Resources

Blog
Earnings
Partner Program

Company

Contact
About
News Release
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. IGMS
    4. >
  4. Forecast

Stock Price Prediction

-
stocks logo
IGMS
-
$
0.000
0.000(0.000%)
    OverviewForecastTechnicalOptionsEarningsFinancialsValuationInsiders

IGMS Similar Chart Price Prediction

The price of IGMS is predicted to go up 5.15%, based on the high correlation periods with RLMD. The similarity of these two price pattern on the periods is 99.8%.

stocks logo

IGMS

stocks logo

RLMD

Up: 5.15%Similarity: 99.8%

IGMS Revenue Forecast

IGMS EPS Forecast

IGMS FAQs

What is bull’s view on IGMS?

IGMS stock has faced significant bearish sentiment recently, with analysts downgrading price targets to as low as $1.50–$2.50 due to the company's decision to halt its primary autoimmune pipeline and reduce its workforce by 73%. The stock currently trades near $2.15, reflecting anticipated cash levels and strategic uncertainty. Bulls may argue for stabilization at these levels, but the lack of clear growth drivers limits upside potential.

What is bear's view on IGMS?

IGMS stock is currently trading at $2.15, reflecting a sharp decline of 65% after the company halted its key clinical programs and announced workforce reductions. Analysts have significantly downgraded the stock, with price targets as low as $1.50, citing the lack of a clear path forward and diminished pipeline value. The bearish view is driven by the company's strategic uncertainty and reduced financial projections, making it a high-risk investment.

What is IGMS revenue forecast for next quarter？

The market consensus for IGMS's revenue in the upcoming quarter is projected to be approximately $2.487M USD.

IGMS VS S&P500

Ask Intellectia about IGMS

IGMS Analyst's Forecast

Stephen Willey

Stifel

Strong Buy → Hold

Price Target

$27 → $2.5

Upside

+19.62%

Stifel downgraded IGM Biosciences to Hold from Buy with a price target of $2.50, down from $27. Th firm cites the company's "surprising decision" to discontinue all further development of its autoimmune and inflammatory disease applications for the downgrade. The strategic pivot will trigger the evaluation of both internal and external/ alternatives and an over 70% workforce reduction, the analyst tells investors in a research note.
Brian Abrahams

RBC Capital

Buy → Hold

Price Target

$20 → $1.5

Upside

-28.23%

Stephen Willey

Stifel

Strong Buy

Price Target

$25 → $27

Upside

+109.63%

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Product
PricingPre Market MoversFinancial AI AgentSwing TradingStock Technical AnalysisStock MonitorCopy Top Investors PortfolioCrypto Technical Analysis
Support
BlogEarningsTerms of UsePrivacy PolicySitemapPartner Program
Start for Free